Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
View original at finance.yahoo.comGilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases -- Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead’s Inflammation Portfolio -- -- Gilead Intends to Enter into a Strategic Collaboration…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
From the outset, we saw the potential for gamgertamig to redefine the standard of care for immune-mediated diseases
60% confidenceWith support from Gilead and Galapagos, we can build on the strong early foundation—leveraging a proven track record in late stage development, launch, and commercialization to accelerate our programs
60% confidenceClinical data suggests BCMA-targeted T cell engagers may reduce inflammation, improve organ-level disease, and enable an immune reset marked by durable, drug-free remission without ongoing immunosuppression
60% confidenceOM336 has demonstrated transformative efficacy and a differentiated safety profile after a single treatment cycle in severe antibody-mediated orphan diseases including autoimmune hemolytic anemia and immune thrombocytopenia
60% confidenceBCMA targeted T cell engagers represent a differentiated approach with the potential to induce durable disease control
60% confidenceThis novel framework complements our expanding inflammation pipeline and reflects our strategy to invest in innovative science that may redefine standards of care
60% confidenceBCMA is a validated target with emerging data demonstrating potentially transformative outcomes in autoimmune diseases
60% confidenceThis acquisition underscores our commitment to advancing transformative therapies for people living with serious autoimmune diseases
60% confidence